We next assessed the antitumor potential of pembrolizumab-Y8 fusion proteins in real-time T cell–mediated cytotoxicity assays against PD-L1-overexpressing tumor cell lines, MDA-MB-231 and A375. This evidence concerns the gene CD274 and neoplasm.